Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Randomised Phase II Trial Data on the Combination of 2nd-line Osimertinib and Bevacizumab Versus Standard of Care Osimertinib in EGFR T790M-mutated Advanced NSCLC

ESMO-Virtual-Plenaries-2021-1000x250-May

Next Edition of the ESMO Virtual Plenaries

Start date
12 May 2021
End date
13 May 2021
Live On
12 May 2021

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

Programme

Wednesday, 12 May 2021

18:15-19:15 CEST

Welcome and introduction, Scientific background and context

Pilar Garrido, University Hospital Ramón y Cajal (IRYCIS), Madrid, Spain

A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

Ross Soo, National University Hospital, Singapore

Critical analysis and perspectives

Edward Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, CA, USA

Discussion and Q&A (i)

Faculty and online audience

Thursday, 13 May 2021

12:00-13:00 CEST (18:00 HKT / 19:00 JST / 20:00 AEST)
Webcast of 12 May presentations, Discussion and Q&A (ii)

Faculty and online audience:

Ben Solomon, Peter MacCallum Cancer Center, Melbourne, Australia

Ross Soo, National University Hospital, Singapore

Edward Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, CA, USA

Tony SK Mok, Prince of Wales Hospital, Hong Kong, China

Hidehito Horinouchi, National Cancer Center - Tsukiji Campus, Chuo-ku,  Japan

If you are interested in attending this event, submit your email below to receive notifications

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings